Discovery & Development US 2026
Hilton San Diego Bayfront, CA
The Power Of Partnerships: Aligning Pharma, Biotech, And Academia To Accelerate Development & Innovation
Panel Discussion• Bridging cultures and goals
• Shared resources and expertise
• Accelerating translation
• How partnerships can streamline moving discoveries from the lab to clinical development and market
Small-Angle X-ray Scattering for Early Detection of High-Concentration Antibody Viscosity
Industry PresentationHT-SAXS predicts viscosity early: Low-q structure factor changes at ≤10 mg/mL reliably flag high-viscosity mAbs long before high-concentration testing is needed
More accurate than kD: SAXS structure factor upturn/downturn directly captures attractive vs repulsive interactions and outperforms kD in viscosity classification (100% vs 82% accuracy)
High-throughput, low sample demand: Automated SAXS enables rapid, scalable developability screening using minimal material, suitable for early discovery workflows
Multi-Agentic AI For Formulation & Late-Stage Preclinical Research
Industry PresentationDesign And Formulation Of Long Acting Entecavir Prodrugs For Improved Hepatitis B Treatment Adherence
Industry PresentationOverview Of The Challenges Of CMC
Industry PresentationWhy Formulations Fail — Lessons Learned Across Modalities
Panel Discussion• Common reasons for failure (e.g., stability, delivery barriers, patient compliance)
• Case studies: when a formulation didn’t meet expectations
• The role of biological barriers (e.g., blood-brain barrier, tissue penetration) in failure
• How early-stage decisions can set projects up for success or failure
• Creating a culture that shares failures constructively
Formulating Next-Gen Biotherapeutics: Strategies To Enhance Stability, Quality, And Scalability
Panel Discussion• Stabilising complex modalities
• Evaluating non-traditional formulation strategies — including lyophilisation, coformulation, microencapsulation, or amorphous systems
Machinability Of Spray Freeze-Dried Engineered Microparticles
Industry PresentationSpray freeze drying enables the production of highly porous engineered powders ideal for thermosensitive molecules, including biologic drugs. The process generates distinctive microstructures that strongly influence flowability, mechanical behavior, and downstream processability. This talk examines how particle architecture governs machinability, highlighting implications for pharmaceutical manufacturing.
RNAi Delivery, LPN, & Conjugate Approaches
Industry PresentationCan Oral Peptides Finally Replace Injections? From Breakthroughs To Biological Limits
Panel Discussion• Is oral delivery of peptides a solved engineering problem or a biological limit?
• What level of oral bioavailability is actually “good enough” for clinical success?
• Will oral GLP-1s redefine the market or remain niche alternatives?
Recent Advances To Improve Bioavailability: Permeability, Solubility
Industry PresentationFrom Formulation To Market: What Makes A Nasal Product Commercially Viable?
Panel DiscussionRecognize how unmet clinical needs and therapeutic advantages determine the commercial success of nasal drug products.
Evaluate the critical interplay between formulation, device design, patient usability, manufacturability, and cost in determining market adoption.
Apply regulatory, scalability, and differentiation considerations early in development to assess the commercial viability of nasal drug products.
mRNA Center of Excellence: Optimization Of Sequencing & Delivery
Industry PresentationDeveloping BBT-101 - A First-In-Class, Intranasal Formulation
Industry PresentationBalancing Biopharmaceutics, Stability & Manufacturability In LAI Suspension Formulation Design
Industry PresentationLow-Cost Production For Proteins & Internasal Delivery
Industry PresentationAI Driven Formulation For Small Molecules
Industry PresentationDealing With High Manufacturing And Product Costs In The Gene Therapy Space
Roundtable DiscussionFrom Oral to Inhaled: Lifecycle Delivery Strategies for Pulmonary Disease Therapeutics
Roundtable DiscussionWhen and why to consider alternative delivery routes as lifecycle extensions for oral drugs
Practical formulation, device, and regulatory considerations when repurposing a candidate for inhalation
Lessons learned and open questions across industry and academia
Unlocking AI/ML In Drug Delivery — Overcoming Data Quality & Access Barriers
Panel Discussion• What types of data are most valuable for formulation and delivery research?
• Current barriers: access, standardization, quality, and reproducibility
• Strategies for data sharing across pharma, biotech, and academia
• Case examples of successful AI/ML applications in drug delivery
• Building collaborations to create usable, high-quality datasets
Delivering Therapies Across The Blood-Brain Barrier
Panel Discussion• Developing optimized BBB models for drug discovery
• Predicting future
• Recent technological advancements & platforms
• Challenges and unities for the delivery of biopharmaceuticals
• Using nasal to brain route
Overcoming Formulation Challenges For Inhaled Biologics
Industry PresentationOligonucleotide Formulation, Design, & Delivery
Industry PresentationBarriers And Biology Of Oral Peptide Delivery
Industry PresentationDeveloping Small Molecule Drugs To Mitigate Cisplatin Toxicities
Industry PresentationRecent Advances To Improve Bioavailability: Permeability, Solubility
Industry PresentationModel-Informed Biopharmaceutics In Formulation Development
Industry PresentationCMC Considerations For Combination Products And Smart Delivery Systems
Industry PresentationBreaking The Bottleneck For Biologics & Small Molecules Drug Delivery
Panel Discussion• What makes oral delivery so attractive—and so difficult—for biologics/oligos?
• Novel approaches: nanoparticle carriers, permeation enhancers, and formulation tricks
• Case studies of progress (in oral biologics
• Balancing patient convenience vs. technical feasibility
• How AI/ML can help accelerate innovation
ABI-171: Exploring Inhaled Delivery As A Lifecycle Strategy For An Oral Anti-Fibrotic Drug In IPF
Industry PresentationOverview of ABI-171 as a novel oral anti-fibrotic therapeutic for IPF with orphan designation and preclinical proof of concept
Rationale for exploring inhaled/intranasal delivery as a lifecycle management strategy: direct pulmonary targeting, potential for reduced systemic exposure, and expanded therapeutic utility
Key formulation and delivery challenges in transitioning an oral candidate to an inhaled route and early learnings
Oral Inhalation Through Nebulizers
Industry PresentationDevelopment In Fever Launched Antibodies
Industry PresentationTranslational Nasal Drug Delivery Platforms for Targeted CNS Therapeutics
Industry PresentationDemystifying Foggin In Lyophilized Products
Industry PresentationThe talk would cover recent work aimed at establishing a mechanistic understanding of factors affecting fogging in freeze-dried products. While fogging is a routinely encountered cosmetic defect in freeze-dried formulations, it can potentially impact container closure integrity. Hence, vials with fogging above the shoulder and neck are often rejected during visual inspection. This, in-turn, can result in high batch reject rates during clinical and commercial manufacturing. The severity of fogging in lyophilized products is impacted by a varied range of factors. These can be broadly classified as: formulation composition, pharmaceutical processing conditions and primary packaging. Hence, a systematic study to investigate the influence of each of these factors on fogging enables a mechanistic understanding and consequently, the design of suitable mitigation strategies.
Utilizing Nanotechnology Approaches
Industry PresentationReal-Time Release Testing
Industry PresentationOcular Biologics Delivery
Industry PresentationAI & In Silico Tools In Formulation Development
Roundtable DiscussionOvercoming Challenges In RNA Delivery
Industry PresentationDesign Considerations For IV In-Use Studies To Support Clinical Administration
Industry PresentationA thoughtful design of in-use studies ensures drug stability and compatibility during dose preparation and clinical administration. An overview of study design considerations such as the regions and number of clinical sites and anticipated dose preparation and administration procedure is presented. A case study walks through an example of in-use studies to support an early phase program with clinical sites in multiple regions, weight-based dosing, and a switch from undiluted to diluted administration.
Inhaled Biologics & Oligonucleotides — Opportunities Beyond The Lungs
Panel Discussion• Technical barriers in formulating inhaled large molecules
• Advances in nasal-to-brain delivery and CNS targeting
• Device/formulation interplay: how inhaler design impacts delivery success
• Regulatory and safety considerations unique to inhaled biologics
• Sustainability considerations (propellants, greener formulations)
Novel Tumour Targeting Peptide Therapies
Industry PresentationInsights Into Successful Industry Clinical Collaborations
Industry Presentation• Why do we establish clinical collaborations with external companies?
• Industry Clinical Collaborations (ICC) at Roche
• Drugs combinations in ICC
• Successes & challenges with commercial drugs & novel combinations
Formulaiton & Delivery Challenges For Oral Peptides
Industry PresentationReimagining Abuse Deterrence Through Controlled-Release Engineering
Industry PresentationThe talk highlights innovation-oriented evaluation strategies, including stress-based dissolution testing, extraction resistance profiling, and kinetic descriptors such as partial area-under-the-curve (pAUC) to characterize early exposure behavior. These tools provide mechanistic insight into how formulation design choices translate into exposure profiles relevant to abuse liability assessment.
Inhaled Delivery Of Biologics
Industry PresentationHigh Dose, High Volume Biologics
Industry PresentationWhere Smart Capital Meets Science: Investing In The Next Wave Of Drug Discovery Innovation
Panel Discussion• How investors evaluate emerging drug discovery technologies
o AI in drug discovery
• What drives funding decisions in a shifting biotech market
• Where capital is flowing next
• How investor are looking at non-dilutive founding
Beyond The Hype: AI, Data & The Industry Shift In Drug Discovery R&D
Panel Discussion• How industry dynamics are reshaping pharma R&D strategy & decision-making
• Digital transformation, AI & data-driven labs of the future
• What leaders need to prioritize to turn innovation into real scientific & business impact
Title TBC
Industry PresentationProtein Stability: A Drug Delivery Formulation Challenge
Industry PresentationmRNA Importance
Industry PresentationProgramming Skeletal Muscle As A Bioreactor: A Platform For Durable In Vivo Delivery Of Therapeutic Proteins
Industry PresentationProgramming Skeletal Muscle As A Bioreactor – Building The Next Generation Of DNA-Encoded Medicines
Roundtable Discussion- Explore the potential of skeletal muscle as a programmable in vivo bioreactor for sustained therapeutic protein production
- Contrast non-viral DNA-based delivery with AAV gene therapy, including differences in payload flexibility, manufacturability, immune barriers, and repeat-dosing potential
- Discuss the therapeutic areas where durable, tunable protein expression could reshape the future of biologics, from rare diseases to chronic conditions and infectious disease countermeasures
Women In Drug Discovery & Development
Panel Discussion• Exploring pathways to leadership, career progression, and influence for women across drug discovery and development organizations
• Addressing barriers to advancement while sharing strategies to foster mentorship, sponsorship, and greater diversity in scientific innovation and decision-making
Solution Provider Presentation
Solution Provider PresentationInnovation to Impact: Market Strategies Driving the Next Wave of Drug Delivery Technologies
Panel Discussion• What actually defines a “successful” delivery innovation in the market?
• From lab breakthrough to commercial product: where do most strategies fail?
• Pharma vs biotech vs academia: who owns the pathway to market?
• Market access and reimbursement as the real gatekeepers of innovation
Solution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationPartnerships, Platforms Or Acquisitions: What Is The Winning Model For Brain Health Innovation?
Panel Discussioncollaboration models that actually work
• When to partner vs acquire vs build internally
• Data-sharing in a competitive landscape
• Public-private partnerships in USA: success stories & failures
Injectable & Sustainable Formulations For Oral Peptides
Roundtable Discussion• Overcoming bioavailability and stability challenges to enable effective oral peptide delivery through advanced injectable-to-oral formulation strategies
• Balancing patient convenience with sustainability by reducing waste, improving manufacturing efficiency, and designing greener peptide delivery systems
Critical Attributes For Successful mRNA Based Drug Products
Roundtable Discussion• What are critical elements for drug substance?
• What makes a good delivery system?
• How sustainable can mRNA-based drug products be?
High Throughput Screening
Industry PresentationAI Rewiring The Future Of Drug Discovery
Industry Presentation• Taking a deep dive into generative AI for molecular design to illustrate individual methods that have transformative implications
• Putting it all together – active learning and multi-property optimisation for multiple drug properties
• Using AI to integrate early and late-stage considerations – agentic AI approaches
• How do we collaborate across the industry to develop these frameworks?
Novel Hit Identification Techniques
Industry PresentationGenerative AI-Guided Selections for GPCR Antibody Discovery
Industry PresentationIntegrating Human-Centric Biology, AI, & New Approach Methodologies For Phase 1 Clinical Trials
Industry PresentationAI In Drug Discovery
Industry PresentationLab Digitalization & AI
Industry PresentationCovalent Drug Discovery; Screening, Characterization, & Discovery
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider Presentation
Afternoon Break & Refreshments
Lunch Break
Morning Break & Refreshments
Close of Day One & Networking Drinks Reception
Lunch Break
End of Event
Morning Break & Refreshments
No sessions found matching your filters.